Friday, October 30, 2026
Via News Knowledge File

NASDAQ

organization100% conf.·synced Oct 30, 2026

Stock exchange where Jayud is listed

14
sourced metrics
1664
relationships
5
stated objectives
8
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Recovery Time From Prior Peak
15years
Stock Price
91.14USD
Index Level
23548.88points
Weekly Return
6percent
Listed Companies
3500companies
Index Change
-1percent
Minimum Bid Price
1.00USD
Market Return
185percent
Apr 4, 2026source
Percent Change
-2.4percent
Mar 27, 2026source
Daily Return
-0.59percent
Mar 25, 2026source
Daily Change
1percent
Feb 25, 2026source
Return
20percent
Dec 26, 2025source
Market Cap Multiple
5times_dotcom_peak
Jan 1, 2025source
Stock Index Decline
80percent
Oct 1, 2002source

Stated objectives

Start tokenization operations

source
by 2026-01-01 00:00:00stated

Obtain approval for 23-hour weekday trading

source
target: 23 hours per weekday stated

Allow stocks to be tokenized and traded on regulated venues

source
stated

Nasdaq expanding into tokenized securities following SEC approval, aiming to bring traditional securities onto the blockchain

source
stated

Nasdaq taking steps toward listing tokenized stocks where on-chain tokens represent real-world equities

source
stated

Relationship graph · 1664 connections

listed on
1083
located in
368
regulates
60
trades on
24
headquartered in
19
Owns
14
Covered by
11
Supplies to
10

Via News coverage

This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com